STADA Arzneimittel AG - M&A Activity 2017

News Details

Ad-hoc | 24 August 2017 18:06

STADA Arzneimittel AG: Entering into negotiations of a domination and profit and loss pooling agreement between STADA Arzneimittel AG and Nidda Healthcare Holding AG

STADA Arzneimittel AG / Key word(s): Miscellaneous

24-Aug-2017 / 18:06 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

Bad Vilbel, August 24, 2017 – Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, has today approached STADA Arzneimittel AG to discuss its intention to establish a domination and profit and loss transfer agreement pursuant to Section 291 ff AktG with Nidda Healthcare Holding AG or a related entity as the controlling company and STADA Arzneimittel AG as the controlled company. The Executive Board of STADA Arzneimittel AG has decided to enter into discussions with the Executive Board of Nidda Healthcare Holding AG on the conclusion of a domination and profit and loss transfer agreement. The minority shareholders of STADA Arzneimittel AG are to receive an offer by Nidda Healthcare Holding AG to purchase their shares against cash compensation and to pay compensation for the duration of the contract. The final form of the settlement scheme and the annual compensation payment in the contract will determine the companies in accordance with the legal requirements and on the basis of a business valuation.

Contact:

STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /

Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]

Or visit us on the internet at www.stada.com

24-Aug-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language:	English
Company:	STADA Arzneimittel AG
	Stadastraße 2-18
	61118 Bad Vilbel
	Germany
Phone:	+49 (0)6101 603- 113
Fax:	+49 (0)6101 603- 506
E-mail:	[email protected]
Internet:	www.stada.de
ISIN:	DE0007251803, DE0007251845,
WKN:	725180, 725184,
Indices:	MDAX
Listed:	Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange